Unveiling NUP98-NSD1 leukemia

2023 Fiscal Year Final Research Report

• Project/Area Number: 22K20842
• Research Category: Grant-in-Aid for Research Activity Start-up
• Allocation Type: Multi-year Fund
• Review Section: 0902:General internal medicine and related fields
• Research Institution: Hokkaido University
• Principal Investigator: Matsukawa Toshihiro 北海道大学, 大学病院, 特任助教 (20963169)
• Project Period (FY): 2022-08-31 – 2024-03-31
• Keywords: NUP98-NSD1

Outline of Final Research Achievements

This study identified NUP98-NSD1-positive acute myeloid leukemia from specimens which collected by the Hokkaido Leukemia Net. We next cloned NUP98-NSD1 and confirmed the full length of the vector by Sanger sequencing.
Then we transfected NUP98-NSD1 into Ba/F3, the human B-cell line, and selected it by puromycin. However, because the expression of the NUP98-NSD1 fusion protein could not be detected by immunoblotting, we tried to transduce other human cell lines.

Free Research Field

血液学

Academic Significance and Societal Importance of the Research Achievements

現在までに主だった成果は挙げられていない。
NUP98-NSD1が大きくなかなかヒト細胞株に遺伝子導入ができていないが、以前より施行している遺伝子導入法ではなく別の方法での遺伝子導入を行っており、NUP98-NSD1陽性ヒト細胞株が確立され、NUP98-NSD1陽性急性骨髄性白血病の発症機構や薬剤耐性機構が解明できれば、予後不良であるNUP98-NSD1陽性急性骨髄性白血病治療における重要な成果となりうると考える。